Rate of COVID‐19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome‐coronavirus 2: Analysis of the American Society of Clinical Oncology Registry

Abstract

Background:The availability of safe and effective COVID-19 vaccines has enabled protections against serious COVID-19 outcomes, which are particularly important for patients with cancer. The American Society of Clinical Oncology Registry enabled the study of COVID-19 vaccine uptake in patients with cancer who were positive for severe acute respiratory syndrome-coronavirus 2.Methods: Medical oncology practices entered data on patients who were in cancer treatment. The cohort included patients who had severe acute respiratory syndrome-coronavirus 2 infection in 2020 and had visits and vaccine data after December 31, 2020. The primary end point was the time to first vaccination from January 1, 2021. Cumulative incidence estimates and Cox regression with death as a competing risk were used to describe the time to vaccine uptake and factors associated with vaccine receipt. Results:The cohort included 1155 patients from 56 practices. Among 690 patients who received the first vaccine dose, 92% received the second dose. The median time to vaccine was 99 days. After adjustment, older patients were associated with a higher likelihood of vaccination compared with patients younger than 50 years in January through March 2021, and age exhibited a linear effect, with older patients showing higher rates of vaccination. Metastatic solid tumors (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.73-0.98) or non-B-cell hematologic

Smartphone sensors for evaluating COVID-19 fear in patients with cancer: a prospective study

“…Most patients in our cohort were fully or partially vaccinated and only 16% of patients were not vaccinated. COVID-19 vaccine uptake in our study was comparable to a previous study that used American Society of Clinical Oncology Registry data (33), revealing that younger age, diagnosis of a metastatic tumor or non-B-cell hematologic malignancies, and co-morbidities were associated with lower vaccine uptake. In our study, non-vaccinated status was higher in patients with prior COVID-19 infection and cervical cancer.…”

Serological Response to COVID-19 Vaccination is Impaired in Adults with Hematologic Malignancies when Compared to Adults with Solid Tumors and HIV: Observations from a Single Tertiary Institution

“…In the US, surveys performed by the Centers for Disease Control and Prevention (CDC) show lower bivalent booster adoption rates in younger adults, people living in rural areas, Americans without health insurance, and in Black and Hispanic Americans. Studies analyzing cancer patients showed that counterintuitively, people with more aggressive cancers were less likely to be vaccinated and that patients with comorbid diseases in addition to cancer were also less likely to be vaccinated [22] , even though their comorbid cardiovascular, gastrointestinal, or autoimmune diseases likely placed them at risk for severe COVID-19 disease. This highlights the importance of utilizing antibody testing in conjunction with consideration for social determinants of health, including level of education and other socioeconomic factors, to identify individuals at highest risk of vaccine hesitancy, risk of vaccine non-response, and complications from COVID-19 disease.…”

COVID-19 Vaccination Rates and Predictors of Uptake Among Adults With Coronary Heart Disease: Insight From the 2022 National Health Interview Survey

“…In a systematic review of studies about COVID-19 vaccination in patients with diabetes mellitus, vaccine hesitation rates of about 30% were reported, with a lack of information mentioned as a significant reason for this finding [7]. Promising uptake in vaccination has however been reported in populations with cancer, with age, multiple comorbidities, and level of education identified as factors driving it [8].…”